Skip to main content
. 2002 Jan;127(1):123–130. doi: 10.1046/j.1365-2249.2002.01728.x

Fig. 5.

Fig. 5

Evolution of sTNFR1 concentrations over time in four HCV-MC patients. Patient 1(a) suffered from a low-severity form of the disease (patient 3 in Table 2). Patients 2(b), 3(c) and 4(d) (patients 10, 1 and 18, respectively, in Table 3) suffered from severe visceral forms of the disease. IFN, interferon; Riba, ribavirin; PE, plasma exchanges; CS, corticosteroids; CP, cyclophosphamide.